Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    TopAbstracts in Cholesterol/Lipid Disorders 11/27/2008 - (DGNews)
    Efficacy of statins in familial hypercholesterolaemia: a long term cohort study - (BMJ)
    TopAbstracts in Cholesterol/Lipid Disorders 11/13/2008 - (DGNews)
    Statin-Associated Myalgia Linked to Vitamin D Deficiency: Presented at AHA - (DGDispatch)
    Colesevelam Safe, Effective in Lowering Cholesterol in Children With Familial Hypercholesterolaemia: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
      Residual CV Risk and Future Treatment Strategies
      Vascular Protection and CB1 Blockade: Evolving Data
      Cardiometabolic Risk and Risk Management
      Understanding Metabolic Syndrome: Knowing the Risks
      Evidence-based Review of Lipid Treatment in 2008

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review
        Familial Hypercholesterolemia with Coarctation of Aorta
        Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        New Cholesterol Absorption Inhibitor Appears Safe, Effective for Hypercholesterolemia

        A DGReview of :"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe , in patients with primary hypercholesterolemia"
        American Journal of Cardiology

        11/29/2002
        By Andrew A. Skolnick


        Ezetimibe, a new cholesterol absorption inhibitor, appears safe and effective for lowering low density lipid cholesterol and improving other key lipid parameters.

        Carlos A. Dujovne, MD, at the Kansas Foundation for Clinical Pharmacology, Overland Park, Kansas, United States, and colleagues conducted a randomised, double-blind, placebo-controlled trial to evaluate the safety and efficacy of the new drug.

        The study involved 892 patients with primary hypercholesterolemia, with low density lipid (LDL) cholesterol levels between 130 to 250 mg/dL and triglycerides at 350 mg/dL or less.

        After two weeks on the National Cholesterol Education Program (NCEP) Step I or a stricter diet, and a four- to eight-week single-blind placebo lead-in, the patients were randomised 3-1 to receive ezetimibe 10 mg or placebo orally each morning for 12 weeks.

        The primary efficacy end point was the percent reduction in direct plasma low density lipid cholesterol from baseline. A total of 434 men and 458 women (ages 18 to 85 years) received randomized treatment (666 ezetimibe 10 mg, 226 placebo). Demographics and baseline characteristics of the ezetimibe and placebo groups were similar, the researchers noted.

        Ezetimibe significantly reduced direct low density lipid cholesterol by a mean of 16.9 percent, compared with an increase of 0.4 percent for placebo (p < .01). Subgroup analysis indicated that response to ezetimibe was generally consistent across all subgroups, regardless of risk-factor status, gender, age, race or baseline lipid profile. Ezetimibe effects on low density lipid cholesterol occurred by the second week and persisted throughout the 12-week treatment period, the investigators reported.

        Compared with placebo, ezetimibe 10 mg also significantly improved calculated LDL cholesterol, apolipoprotein B, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and high density lipid-3 cholesterol (p < 0.01).

        There were no differences in laboratory or clinical safety parameters, or gastrointestinal, liver or muscle side effects between the drug and placebo groups.

        "Ezetimibe 10 mg/day is well tolerated, reduces LDL cholesterol approximately 17 percent and improves other key lipid parameters," the researchers concluded.
        Am J Cardiol 2002; 90: 1092-1097. "Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe , in patients with primary hypercholesterolemia"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send